Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

BACKGROUND: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Wagener-Ryczek, Svenja, Heydt, Carina, Süptitz, Juliane, Michels, Sebastian, Falk, Markus, Alidousty, Christina, Fassunke, Jana, Ihle, Michaela Angelika, Tiemann, Markus, Heukamp, Lukas, Wolf, Jürgen, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216404/
https://ncbi.nlm.nih.gov/pubmed/32397977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06920-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares